Attached files

file filename
EX-3.1 - EXHIBIT 3.1 - OPIANT PHARMACEUTICALS, INC.v395580_ex3-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________

 

FORM 8-K

___________

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 26, 2014

 

LIGHTLAKE THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Nevada   333-139915   N/A
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employee Identification No.)

 

96-98 Baker Street, First Floor, London, England W1U 6TJ

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: 44 (0) 203 617 8739

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On November 26, 2014, Lightlake Therapeutics Inc. (the “Company”) amended its articles of incorporation (the “Articles”) to increase the number of shares of common stock, par value $0.001 per share, that the Company is authorized to issue from 200,000,000 to 1,000,000,000.

 

The foregoing description of the amended Articles is qualified in its entirety by reference to the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description of Exhibit
3.1   Certificate of Amendment.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Lightlake Therapeutics Inc.  
     
Dated: December 1, 2014 By: /s/ Dr. Roger Crystal  
  Name: Dr. Roger Crystal  
  Title:   President and Chief Executive Officer